İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2012

The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis

World Journal of Surgical Oncology

YÖKSİS OpenAlex Açık erişim · gold SJR Q2 JCR Q3 Atıf 12 Yüzdelik 73.7% FWCI 0.66
Yıl
2012
ISSN
1477-7819
Tür
article

Veri kaynağı ayrımı

  • YÖKSİS YÖKSİS makale kaydı
  • OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

İngilizce (OpenAlex)

BACKGROUND: Although neoadjuvant chemotherapy (NCT) is widely used, it is not clear which subgroup of locally advanced non-small-cell lung cancer (NSCLC) patients should be treated with this approach, and if a particular benefit associated with NCT exists. In this study, we aimed to investigate the potential correlates of benefit from NCT in patients with NSCLC. METHODS: All randomized clinical trials (RCTs) utilizing a NCT arm (without radiotherapy) versus a control arm before surgery were included for metaregression analysis. All regression analyses were weighed for trial size. Separate analyses were conducted for trials recruiting patients with different stages of disease. Previously published measures of treatment efficacy were used for the purpose of this study, regardless of being published in full text or abstract form. RESULTS: A total of 14 RCTs, consisting of 3,615 patients, were selected. Histology, stage, various characteristics of the NCT protocol, and different trial features including trial quality score were not associated with the benefit of NCT. However, in trials of stage 3 disease only, there was a greater benefit in terms of reduction in mortality from NCT, if protocols with three chemotherapeutics were used (B = -0.18, t = -5.25, P = 0.006). CONCLUSIONS: We think that patients with stage 3 NSCLC are served better with NCT before surgery if protocols with three chemotherapy agents or equally effective combinations are used. In addition, the effect of neoadjuvant chemotherapy is consistent with regard to disease and patient characteristics. This finding should be tested in future RCTs or individual patient data meta-analyses.

Konular

  • Lung Cancer Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Radiomics and Machine Learning in Medical Imaging

Birincil konu Lung Cancer Diagnosis and Treatment

Yazarlar

  1. HAKAN BOZCUK
  2. HÜSEYİN ABALI
  3. HASAN ŞENOL COŞKUN
  4. ADNAN AYDINER
  5. AHMET ÇİNKAYA
  6. AHMET DEMİRKAZIK
  7. AHMET ÖZET GAZİ ÜNİVERSİTESİ
  8. AHMET YOLCU
  9. ARZU BALKAN
  10. AYHAN ÇAVDAR
  11. AYŞEGÜL ÜÇÜNCÜ KEFELİ
  12. BAŞAK OYAN ULUÇ
  13. BESTE ATASOY
  14. HATİCE MİRAÇ BİNNAZ DEMİRKAN
  15. BÜLENT YALÇIN
  16. CELALETTİN EROĞLU
  17. DENİZ YALMAN
  18. DİCLEHAN KILIÇ
  19. DİDEM TUNALI
  20. DİNÇER FIRAT
  21. ERDOĞAN SELÇUK ŞEBER
  22. EMEL ÜÇGÜL ÇAVUŞOĞLU
  23. ENGİN ULUKAYA
  24. ESRA KAYTAN SAĞLAM BİRUNİ ÜNİVERSİTESİ
  25. EVRİM TEZCANLI
  26. IŞIL EZGİ ERYILMAZ
  27. HİDAYET FAZİLET DİNÇBAŞ
  28. FERHAT TELLİ
  29. PERRAN FULDEN YUMUK
  30. GÜL BAŞARAN
  31. HALE BAŞAK ÇAĞLAR
  32. İBRAHİM HALİL SÖNMEZ
  33. HASAN YILMAZ
  34. HÜSEYİN ENGİN
  35. KAAN HELVACI
  36. KEMAL SÖNMEZ
  37. LOKMAN KORAL
  38. MEHMET ARTAÇ
  39. MEHMET FUAT EREN
  40. MUHARREM KOÇAR
  41. MEHMET MURAT BEYZADEOĞLU
  42. MUSTAFA AKIN
  43. MUSTAFA BENEKLİ
  44. MUSTAFA CENGİZ
  45. MUSTAFA ERMAN
  46. MUSTAFA YILDIZ
  47. MUTLU DOĞAN
  48. SALİH MÜJDAT BALKAN
  49. NİL ERAKTUĞ
  50. OLÇUN ÜMİT ÜNAL
  51. ORHAN ŞENCAN
  52. ÖZGE PETEK ERPOLAT
  53. PINAR SAİP
  54. SAADETTİN KILIÇKAP
  55. SAİT OKKAN
  56. SEMRA PAYDAŞ
  57. SÜREYYA SARIHAN
  58. ŞEREF KÖMÜRCÜ
  59. TACİSER DEMİRKASIMOĞLU
  60. TANER KORKMAZ
  61. TARKAN YETİŞYİĞİT
  62. TUĞBA YAVUZŞEN
  63. TÜRKKAN EVRENSEL
  64. TÜLAY AKMAN
  65. MEHMET UFUK ABACIOĞLU ACIBADEM MEHMET ALİ AYDINLAR ÜNİVERSİTESİ
  66. UMUT KEFELİ
  67. ÜNAL EGELİ
  68. YEŞİM ELGİN
  69. YUSUF BARAN
  70. ZEYNEP BULUT